H ypertrophic obstructive cardiomyopathy (HOCM) presents with increased left ventricular outflow tract (LVOT) gradient. In most cases, basal septal hypertrophy and systolic anterior motion (SAM) of the anterior mitral leaflet are the key components to LVOT obstruction. The goal of septal reduction therapy (SRT), an accepted treatment modality, is to overcome this obstruction. Although myectomy is a well-established, effective surgical technique for SRT, transcoronary alcohol septal ablation (TASA) is an alternative for patients who have refused surgery or who are high risk for surgery. [1] [2] [3] However, a significant limitation of TASA is reliance on coronary anatomy to provide access to ablation target. The ratio of septal vessel anatomy unsuitable for TASA procedure varies from 1% to 2% up to 15% in the relevant literature. [4, 5] Endocardial septal ablation (ESA) of anterior mitral leaflet and septal contact point has been used as an alternative SRT in a small number of patients. However, precise targeting of SAM-septal contact area is imperative for success of the procedure. Presently described is successful management of HOCM in a 49-year-old man who underwent ESA.
CASE REPORT
A 49-year-old male presented at the clinic with complaints of dyspnea (New York Heart Association [NYHA] functional class III) and angina (Canadian Cardiovascular Society grade III). He had been in follow-up with symptomatic HOCM for 5 years despite maximum doses of metoprolol. Resting transthoracic echocardiography (TTE) (E33 xMATRIX; Philips Healthcare, Inc., Andover, MA, USA) revealed asymmetrical septal hypertrophy (Figure 1a ). In addition, (Figure 2a) . Gradient increased to 200 mmHg after submaximal exercise electrocardiography.
Patient had undergone dual intracardiac defibrillator (ICD) implantation for primary prevention due to massive septal hypertrophy (32 mm) 1 year previously. We programmed ICD with short A-V delay to cause negative inotropic effect and some outflow tract opening due to delayed activation of the basal septum with 100% dyssynchronous pacing from right ventricle. Gradient reduction or symptomatic improvement was not achieved. Surgical myectomy was offered; however, the patient declined the procedure. Although angiographic and contrast echocardiographic evaluations revealed significant spillover of contrast medium into collateral branches, TASA procedure was proposed. Due to refusal of TASA, we then decided to perform ESA. The patient was informed in detail and gave his consent in written form.
Ablation procedure
Procedure was performed under local anesthesia. Following placement of 2 venous and 1 arterial sheaths, the patient was heparinized (100 U/kg) and dosage was adjusted to maintain activated clotting time of between 250 and 300 seconds. Both ventricles were mapped using EnSite NavX system (St Jude Medical, Inc., St. Paul, MN, USA) ( Figure 3 ). First, coronary sinus catheter was inserted via the right femoral vein as reference point for electroanatomic mapping system. Quadripolar catheter was inserted via the right femoral vein into the right ventricular apex for backup pacing. To prevent inverting induction of complete heart block or bundle branch block, we navigated the tip of the ablation catheter as far away as possible from Hisbundle and left bundle branch regions, marked with a "tag" in the EnSite NavX system.
Radiofrequency ablation was performed with 4-mm, irrigated-tip ablation catheter (Therapy Cool Flex; St. Jude Medical Inc., St Paul, MN, USA) at flow rate of 20 mL/min. Ablation via left ventricle (LV) was chosen with the idea that LV gradient reduction would be best achievable by ablating contact point of the anterior mitral leaflet and left side of the interventricular septum. Retrograde, transaortic approach was used for the ablation procedure.
Location of the ablation catheter was defined using TTE guidance (Figure 1b) . When ablation catheter approached contact points, "tag" was used to mark sites in the mapping system as ablation targets. A total of 38 radiofrequency pulses were delivered to the left ventricular septum (impedance range: 98-117 Ohm; Gradient recovered to baseline value within 10 seconds after every pulse. After 20 pulses, resting gradient was reduced from 100 to 20 mmHg ( Figure  2a-d) . Although no further decrease was seen in gradient, ablation area was expanded to 2 cm 2 . Gradient in LVOT remained constant after waiting for a period of 30 minutes the last radiofrequency pulse. Total procedure time and fluoroscopy time were 125 minutes and 13 minutes, respectively. No left bundle branch block or atrioventricular block occurred during or after procedure. Myocardial enzyme levels were significantly increased at 24 hours after procedure (Table 1) . Gradient in LVOT was 35 mmHg at rest and 75 mmHg after exercise stress test on first day after the procedure. At the end of 5 days of follow-up, the patient was discharged with gradient of 40 mmHg. In first and third months of follow-up, LVOT gradient was calculated at 40 mmHg and 20 mmHg, respectively. At the end of 3 months, SAM had entirely disappeared in Mmode echocardiography, and NYHA functional class had improved from III to I (Figure 4 ).
DISCUSSION
Elevated LVOT gradient (usually defined as peak gradient ≥30 mmHg) is present in 20% to 30% of hypertrophic cardiomyopathy cases at rest, and in up to 70% with exercise provocation. [6] It is associated with higher mortality when compared with matched hypertrophic cardiomyopathy patients without gradient. [6] In a recently published study, it was demonstrated that removing gradient may have beneficial effect on survival. [7] In most cases, narrowing of LVOT by asymmetric septal hypertrophy is exacerbated by contact of the anterior mitral valve leaflet with the interventricular septum due to SAM of the anterior mitral leaflet. Contact between anterior mitral valve leaflet and interventricular septum has amplifying effect on LVOT gradient. This SAM-septal contact area is the target of ESA procedure.
It is well known that radiofrequency lesion size is a function of radiofrequency power level and exposure time. [8, 9] Furthermore, irrigated-tip catheters may allow for creation of larger lesions by increasing the power that can be delivered without coagulum formation. [10] To interrupt the SAM-septal feedback mechanism and reduce LVOT gradient, small amount of damage created by radiofrequency energy may be enough. However, the location of tissue damage seems to be at least as important as size.
In the first human experience, Lawrenz et al. [11] performed ESA on 3 highly symptomatic HOCM patients. In this case series, they used fluoroscopy guidance to detect obstructed septal area. Emmel et al. [12] performed a similar procedure on 2 children via LV approach. In addition, they tried to localize the His bundle and left bundle branch using LocaLisa mapping system (Medtronic, Inc., Minneapolis, MN, USA). As an alternative ablative energy source, cryoenergy was used by Keane et al. [13] Acute procedural success was achieved in 2 of the 3 cases. Similar successful results have been presented by other authors, too. [14, 15] In 2011, Lawrenz et al. [14] presented the results of ESA in 19 adult patients with HOCM. In that study, they navigated the tip of the ablation catheter using the CARTO (Biosense Webster, Inc., Diamond Bar, 
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CA, USA) electroanatomical mapping system. Procedure was performed via right ventricular approach in 10 patients and LV approach in 9 patients. They found similar procedural results with both left-sided and right-sided approach for gradient reduction. After 6 months, NYHA functional class improved from 3.0±0.0 to 1.6±0.7 (p<0.01), 6-minute walking distance improved by 58 m (413±129 m at baseline; 458±108 m immediately after ESA; 471±139 m after 6 months; p<0.019). As a remarkable finding, complete heart block occurred in 4 patients (21%) with permanent pacemaker dependency. All patients received dual-chamber pacemaker and were still pacemaker-dependent after 6 months. Results of this study show that heart block risk may be greater in ESA than in TASA procedure.
Exact localization of SAM-interventricular septum contact point is the most important part of ESA procedure. Although transesophageal or intracardiac echocardiography was used in previous studies, our case demonstrates that TTE may provide images of sufficient quality for ESA. On the basis of published studies, left-sided approach seems to be reasonable for targeted ablation of contact point of anterior mitral leaflet and interventricular septum. Results of present case support this hypothesis. At the end of 3 months follow-up, there was clear decrease in intraventricular gradient both at baseline (reduction by 80%) and after postextrasystolic provocation (30%). SAM due to LVOT obstruction was totally resolved on M-mode echocardiography, which corresponded to a remarkable widening of LVOT. In addition, similar to the after septal reduction procedures, there was significant improvement in functional capacity (from NYHA class III to class I). Significant postprocedural increase in cardiac enzymes may be evidence of endomyocardial injury induced by radiofrequency energy, which results in similar release of creatine kinase compared with alcohol septal ablation.
Clinical worsening and significant increase in LVOT gradient observed 2 days after the procedure may be proof that ablation was given the targeted site. Results of present case may be interpreted to indicate that ERSFA could create localized myocardial scar on contact point of anterior mitral leaflet and interventricular septum using TTE guidance. Also, electroanatomical mapping used in this case may preserve atrioventricular and bundle branch conduction, as well as enable exact lesion placement. This approach is the first in the relevant literature. Although significant reduction of septal mass was not observed after ESA procedure, severe decrease in LVOT gradient may be attributed to localized reduction of endomyocardial tissue at contact point, which is the primary mechanism responsible for dynamic obstruction of LVOT.
Conclusion
Although there are some published articles, the nature of these studies is not enough to make a suggestion for routine clinical usage of ESA. Further large-scale studies are needed to clarify this issue. Furthermore, it should be noted that ESA should only be considered when surgical myectomy is not an option for the patient after unsuccessful TASA procedure.
